CureVac announced the completion of an 80 million financing round with its main investor, dievini Hopp BioTech Holding.
In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC), respectively.
Additionally, CureVac will intensify the development of its prophylactic vaccines and adjuvants for infectious diseases.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard– latest trends in big pharma deal making activity